clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2024-2-3-53-61clinicaloncology-76Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSТечение злокачественной феохромоцитомы. Клинический случайCourse of malignant pheochromocytoma. Clinical casehttps://orcid.org/0009-0002-0086-8590СальниковаМ. М.SalnikovaM. M.

Сальникова Мария Михайловна

180004, г. Псков, ул. Вокзальная, д. 15а

Salnikova Maria Mikhailovna

st. Vokzalnaya, 15a, Pskov, 180004

MariaMSalnikova@yandex.ruГБУЗ «Псковский областной клинический онкологический диспансер»РоссияPskov Regional Oncology DispensaryRussian Federation202427012025235361Copyright © Сальникова М.М., 20252025Сальникова М.М.Salnikova M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/76

Феохромоцитомы (ФХ) — редкие катехоламин-секретирующие нейроэндокринные опухоли, почти в 40% случаев имеющие наследственную природу. Симптомы феохромоцитомы обусловлены избыточным производством катехоламинов или масс-эффектом. Частота метастазирования ФХ может достигать 25%. У пациентов с феохромоцитомой в 4 раза выше риск возникновения других злокачественных новообразований (у мужчин в  основном диагностируется рак печени, желчевыводящих путей и  опухоли центральной нервной системы). В данной статье рассмотрен клинический случай первично-множественного течения феохромоцитомы и рака желудка. Основная цель статьи — повысить клиническую настороженность и подчеркнуть актуальность проблемы дифференциальной диагностики и лечения при прогрессировании феохромоцитомы после длительного безрецидивного периода.

Pheochromocytomas (PH) are rare catecholamine-secreting neuroendocrine tumors, which are hereditary in almost 40% of cases. Symptoms of pheochromocytoma are caused by excessive production of catecholamines or mass effect. The frequency of metastasis of PH can reach 25%. Patients with pheochromocytoma have a 4-fold higher risk of developing other malignant neoplasms (in men, liver cancer, biliary tract cancer, and central nervous system tumors are mainly diagnosed).

This article discusses a case of primary multiple change pheochromocytoma and gastric cancer. The main objective of the article is to increase clinical alertness and relevance of the problems of differential diagnosis and treatment in the progression of pheochromocytoma after a long relapse-free period.

феохромоцитоманадпочечникрак желудкадиагностикалекарственное лечениеpheochromocytomaadrenal glandgastric cancerdiagnosticsdrug treatmentСтатья подготовлена без спонсорской поддержки.The article was prepared without sponsorship.ReferencesРумянцев П.О., Языкова Д.Р., Слащук К.Ю., Дегтярев М.В., Ясюченя В.С., Серженко С.С., Шеремета М.С., Дедов И.И. Персонализированная диагностика хромаффинных опухолей (феохромоцитома, параганглиома) в онкоэндокринологии // Эндокринная хирургия. 2018. Т. 12, № 1. С. 19–39. doi: 10.14341/serg9731.Rumyantsev P.O., Yazykova D.R., Slashchuk K.Yu., Degtyarev M.V., Yasyuchenya V.S., Serzhenko S.S., Sheremeta M.S., Dedov I.I. Personalized diagnosis of chromaffin tumors (pheochromocytoma, paraganglioma) in oncoendocrinology. Endocrine surgery, 2018, Vol. 12, No. 1, pp. 19–39 (In Russ.)Neumann H.P., Bausch B., McWhinney S.R. et al. Germ-line mutations in nonsyndromic pheochromocytoma // N. Engl. J. Med. 2002. Vol. 346, No. 19. Р. 1459–1466. doi: 10.1056/NEJMoa020152.Neumann H.P., Bausch B., McWhinney S.R. et al. Germ-line mutations in nonsyndromic pheochromocytoma // N. Engl. J. Med. 2002. Vol. 346, No. 19. Р. 1459–1466. doi: 10.1056/NEJMoa020152.Dahia P.L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity // Nat. Rev. Cancer. 2014. Vol. 14, No. 2. Р. 108–119. doi: 10.1038/nrc3648.Dahia P.L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity // Nat. Rev. Cancer. 2014. Vol. 14, No. 2. Р. 108–119. doi: 10.1038/nrc3648.Cascon A, Inglada-Perez L, Comino-Mendez I, et al. Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients // Endocr. Relat. Cancer. 2013. Vol. 20, No. 3. Р. L1–6. doi: 10.1530/ERC-12-0339.Cascon A, Inglada-Perez L, Comino-Mendez I, et al. Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients // Endocr. Relat. Cancer. 2013. Vol. 20, No. 3. Р. L1–6. doi: 10.1530/ERC-12-0339.Harari A., Inabnet W.B. Malignant pheochromocytoma: a review // The American Journal of Surgery. 2011. Vol. 201, No. 5. Р. 700–708. doi: 10.1016/j.amjsurg.2010.0Harari A., Inabnet W.B. Malignant pheochromocytoma: a review // The American Journal of Surgery. 2011. Vol. 201, No. 5. Р. 700–708. doi: 10.1016/j.amjsurg.2010.0Kopetschke R., Slisko M., Kilisli A. et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma // Eur. J. Endocrinol. 2009. Vol. 161, No. 2. Р. 355–361. doi: 10.1530/EJE-09-0384.Kopetschke R., Slisko M., Kilisli A. et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma // Eur. J. Endocrinol. 2009. Vol. 161, No. 2. Р. 355–361. doi: 10.1530/EJE-09-0384.Кiernan C.M., Solorzano C.C. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment // Surg. Oncol. Clin. N. Am. 2016. Vol. 25. Р. 119–138.Кiernan C.M., Solorzano C.C. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment // Surg. Oncol. Clin. N. Am. 2016. Vol. 25. Р. 119–138.Dahia P.L. Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once! // Cancer Cell. 2017. Vol. 31. Р. 159–161.Dahia P.L. Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once! // Cancer Cell. 2017. Vol. 31. Р. 159–161.Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects // Endocr. Rev. 2003. Vol. 24, No. 4. Р. 539–553. doi: 10.1210/er.2002-0013Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects // Endocr. Rev. 2003. Vol. 24, No. 4. Р. 539–553. doi: 10.1210/er.2002-0013Falhammar H., Kjellman M., Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center // Endocr. Connect. 2018. Vol. 7, No. 1. Р. 186–192.Falhammar H., Kjellman M., Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center // Endocr. Connect. 2018. Vol. 7, No. 1. Р. 186–192.Baguet J.P., Hammer L., Mazzuco T.L. et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients // Eur. J. Endocrinol. 2004. Vol. 150, No. 5. Р. 681–686.Baguet J.P., Hammer L., Mazzuco T.L. et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients // Eur. J. Endocrinol. 2004. Vol. 150, No. 5. Р. 681–686.Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center // Endocrine. 2018. Vol. 62, No. 3. Р. 566–575.Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center // Endocrine. 2018. Vol. 62, No. 3. Р. 566–575.Unger N., Deutschbein T., Walz M.K, Mann K., Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas // Horm. Metab. Res. 2009. Vol. 41, No. 9. Р. 676–679.Unger N., Deutschbein T., Walz M.K, Mann K., Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas // Horm. Metab. Res. 2009. Vol. 41, No. 9. Р. 676–679.Van Berkel A., Lenders J.W., Timmers H.J. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma // Eur. J. Endocrinol. 2014. Vol. 170, No. 3. Р. R109-R119.Van Berkel A., Lenders J.W., Timmers H.J. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma // Eur. J. Endocrinol. 2014. Vol. 170, No. 3. Р. R109-R119.D’Herbomez M., Forzy G., Bauters C. et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas // Eur. J. Endocrinol. 2007. Vol. 156, No. 5. Р. 569–575.D’Herbomez M., Forzy G., Bauters C. et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas // Eur. J. Endocrinol. 2007. Vol. 156, No. 5. Р. 569–575.Tufton N., White G., Drake W.M. et al. Diffusionweighted imaging (DWI) highlights SDHB-related tumours: a pilot study // Clin. Endocrinol. (Oxf). 2019. Vol. 91, No. 1. Р. 104–109.Tufton N., White G., Drake W.M. et al. Diffusionweighted imaging (DWI) highlights SDHB-related tumours: a pilot study // Clin. Endocrinol. (Oxf). 2019. Vol. 91, No. 1. Р. 104–109.Luster M., Karges W., Zeich K. et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma // Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 37, No. 3. Р. 484–493. doi: 10.1007/s00259-009-1294-7.Luster M., Karges W., Zeich K. et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma // Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 37, No. 3. Р. 484–493. doi: 10.1007/s00259-009-1294-7.Lenders J.W., Duh Q.Y., Eisenhofer G. et al.; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab. 2014. Vol. 99, No. 6. Р. 1915–1942.Lenders J.W., Duh Q.Y., Eisenhofer G. et al.; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab. 2014. Vol. 99, No. 6. Р. 1915–1942.Lenders J.W.M., Kerstens M.N., Amar L. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension // J. Hypertens. 2020. Vol. 38, No. 8. Р. 1443–1456.Lenders J.W.M., Kerstens M.N., Amar L. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension // J. Hypertens. 2020. Vol. 38, No. 8. Р. 1443–1456.Hamidi O., Young W.F. Jr, Iñiguez-Ariza N.M. et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years // J. Clin. Endocrinol. Metab. 2017. Vol. 102, No. 9. Р. 3296–3305.Hamidi O., Young W.F. Jr, Iñiguez-Ariza N.M. et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years // J. Clin. Endocrinol. Metab. 2017. Vol. 102, No. 9. Р. 3296–3305.Roman-Gonzalez A., Zhou S., Ayala-Ramirez M. et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma // Ann. Surg. 2018. Vol. 268, No. 1. Р. 172–178.Roman-Gonzalez A., Zhou S., Ayala-Ramirez M. et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma // Ann. Surg. 2018. Vol. 268, No. 1. Р. 172–178.Khorram-Manesh A., Ahlman H., Nilsson O. еt al. Mortality associated with pheochromocytoma in a large Swedish cohort // Eur. J. Surg. Oncol. 2004. Vol. 30. Р. 556–559.Khorram-Manesh A., Ahlman H., Nilsson O. еt al. Mortality associated with pheochromocytoma in a large Swedish cohort // Eur. J. Surg. Oncol. 2004. Vol. 30. Р. 556–559.Lehnert H., Hahn K., Dralle H. [Benign and malignant pheochromocytoma] // Internist (Berl.). 2002. Vol. 43. Р. 196, 199–209. 24. Mei L. et al. Malignant Paraganglioma // Horm. Metab. Res. 2019. Vol. 51. Р. 451–457.Lehnert H., Hahn K., Dralle H. [Benign and malignant pheochromocytoma] // Internist (Berl.). 2002. Vol. 43. Р. 196, 199–209.Mei L. et al. Malignant Paraganglioma // Horm. Metab. Res. 2019. Vol. 51. Р. 451–457.Mei L. et al. Malignant Paraganglioma // Horm. Metab. Res. 2019. Vol. 51. Р. 451–457.

The authors declare that there are no conflicts of interest present.